The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model

Martin Hoyle; Louise Crathorne; Jaime Peters; Tracey Jones-Hughes; Chris Cooper; Mark Napier; Paul Tappenden; Chris Hyde

The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model

Martin Hoyle, Louise Crathorne, Jaime Peters, Tracey Jones-Hughes , Chris Cooper, Mark Napier, Paul Tappenden, Chris Hyde

Research output: Book/Report › Commissioned report

Original language	English
Publisher	University of Exeter
Number of pages	214
Publication status	Published - 2011
Externally published	Yes

Access to Document

https://www.nice.org.uk/guidance/ta242/documents/colorectal-cancer-metastatic-2nd-line-cetuximab-bevacizumab-and-panitumumab-review-assessment-report3

Cite this

Hoyle, M., Crathorne, L., Peters, J., Jones-Hughes , T., Cooper, C., Napier, M., Tappenden, P., & Hyde, C. (2011). The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model. University of Exeter. https://www.nice.org.uk/guidance/ta242/documents/colorectal-cancer-metastatic-2nd-line-cetuximab-bevacizumab-and-panitumumab-review-assessment-report3

Hoyle, Martin ; Crathorne, Louise ; Peters, Jaime et al. / The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118) : a systematic review and economic model. University of Exeter, 2011. 214 p.

@book{2aec23dd934b4c53afa01741ba0a5eb3,

title = "The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model",

author = "Martin Hoyle and Louise Crathorne and Jaime Peters and Tracey Jones-Hughes and Chris Cooper and Mark Napier and Paul Tappenden and Chris Hyde",

year = "2011",

language = "English",

publisher = "University of Exeter",

}

Hoyle, M, Crathorne, L, Peters, J, Jones-Hughes , T, Cooper, C, Napier, M, Tappenden, P & Hyde, C 2011, The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model. University of Exeter. <https://www.nice.org.uk/guidance/ta242/documents/colorectal-cancer-metastatic-2nd-line-cetuximab-bevacizumab-and-panitumumab-review-assessment-report3>

The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model. / Hoyle, Martin; Crathorne, Louise; Peters, Jaime et al.
University of Exeter, 2011. 214 p.

Research output: Book/Report › Commissioned report

TY - BOOK

T1 - The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118)

T2 - a systematic review and economic model

AU - Hoyle, Martin

AU - Crathorne, Louise

AU - Peters, Jaime

AU - Jones-Hughes , Tracey

AU - Cooper, Chris

AU - Napier, Mark

AU - Tappenden, Paul

AU - Hyde, Chris

PY - 2011

Y1 - 2011

UR - https://www.nice.org.uk/guidance/ta242

M3 - Commissioned report

BT - The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118)

PB - University of Exeter

ER -

Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M et al. The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model. University of Exeter, 2011. 214 p.

Access to Document

Other files and links

Cite this